TREK-1 Neural Reset Protocol (Research)
Target the TREK-1 potassium channel to disinhibit serotonergic firing, enhance neurogenesis, and restore mood resilience. Complemented by GABAergic anxiolysis (Selank) and BDNF upregulation (Semax) for a multi-axis neural rebalancing approach.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.
Protocol Stack
Spadin
PrimaryDose
Experimental β not established in humans
Frequency
Daily intranasal or SC (research protocol)
Timing
Morning
Duration
4 weeks; very short half-life (~20 min) requires optimised delivery
Selank
SupportingDose
250β500 mcg
Frequency
Daily intranasal
Timing
Morning or early afternoon
Duration
4 weeks
Semax
OptionalDose
200β600 mcg
Frequency
Daily intranasal
Timing
Morning
Duration
4 weeks, then 2-week break
Monitoring Parameters
- βValidated depression scale (PHQ-9 or MADRS) β baseline, weekly
- βAnxiety scale (GAD-7) β baseline, weekly
- βSleep quality (Pittsburgh Sleep Quality Index) β baseline, week 2, week 4
- βCognitive function: verbal fluency, attention (Trail Making Test)
- βBDNF plasma levels (optional, research context) β baseline and week 4
- βECG β baseline (to rule out TREK-1-related cardiac conduction effects)
- βBlood pressure and heart rate β weekly
Expected Outcomes
Days 3β7: Potential rapid anxiolytic effect (Selank onset); early mood improvement possible (faster than SSRI class)
Week 2: PHQ-9/MADRS improvement expected if Spadin is active β serotonergic response observable
Week 4: Full assessment of antidepressant and anxiolytic response; decision on continuation vs. cycle break
Post-cycle: Neurogenesis effects (hippocampal volume changes) only measurable over months β MRI research endpoint
Contraindications
- βTIER 4 β Spadin has no human clinical trial data. For research/educational purposes only.
- βConcurrent MAOI therapy (absolute β serotonin syndrome risk)
- βActive serotonin syndrome or history thereof
- βBipolar disorder without mood stabiliser coverage (risk of switch to mania)
- βKnown cardiac arrhythmia (TREK-1 expressed in cardiac tissue)
- βActive suicidal ideation β requires inpatient setting
- βPregnancy and breastfeeding
Clinical Notes
Spadin's mechanism is conceptually novel: unlike SSRIs that block serotonin reuptake, Spadin removes tonic inhibition from serotonergic neurons by blocking TREK-1 channels. This is analogous to taking the brakes off rather than pressing the accelerator β and may explain the faster onset observed in mice (3 days vs. 14β21 days for fluoxetine). Selank (anxiolytic, GABAergic modulation + BDNF) and Semax (BDNF upregulation, dopaminergic/serotonergic enhancement) were chosen as mechanistically complementary: Spadin disinhibits 5-HT firing, Semax increases BDNF to sustain neuroplasticity, and Selank reduces the anxiety component that frequently co-presents with depression. The critical delivery challenge for Spadin is its ~20 min plasma half-life; intranasal delivery may provide better CNS bioavailability than SC.
Case Study
Clinical Practice Example
Male, 38, with major depressive disorder, HAM-D score 24 (severe). Failed two SSRI trials (sertraline, escitalopram) and one SNRI (venlafaxine). No current antidepressant. PHQ-9: 19. Enrolled in hypothetical research protocol. Week 1: Selank 500 mcg/day intranasal β GAD-7 dropped from 16 to 11 by day 5. Week 2: Spadin added (experimental intranasal dose) β PHQ-9 13 by day 14. Semax 400 mcg added at week 2. Week 4: PHQ-9 7 (mild), GAD-7 5, Trail Making Test B improved by 22 seconds. Patient described mood as 'the first time in two years I feel like myself.' Note: Hypothetical educational case β no human trial data for Spadin exists.